WO2025163665 - STABLE PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE
National phase entry is expected:
Publication Number
WO/2025/163665
Publication Date
07.08.2025
International Application No.
PCT/IN2025/050093
International Filing Date
28.01.2025
Title **
[English]
STABLE PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE
[French]
COMPOSITIONS PHARMACEUTIQUES STABLES D’ABIRATÉRONE
Applicants **
DR. REDDY’S LABORATORIES LIMITED
Inventors
PANIGRAHI, Dhananjay
SAKA, Raju
VENUGOPAL, Hariharan
CHOUDHURY, Anup Avijit
NAIDU, Venkat Ramana
Priority Data
202441005734
29.01.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2533 | |
| EPO | Filing, Examination, Granting | 19319 | |
| Japan | Filing, Examination, Granting | 2636 | |
| South Korea | Filing, Examination, Granting | 3095 | |
| USA | Filing, Examination, Granting | 7940 |
Total:
35,523
Contact Us
Abstract[English]
The present invention relates to a stable pharmaceutical composition of abiraterone or pharmaceutically acceptable salt thereof. Specifically, it relates to a stable pharmaceutical composition comprising a nanosuspension of abiraterone or pharmaceutically acceptable salt thereof that reduces the dose, lessen the pill burden, enhance the bioavailability of abiraterone in fasting conditions and reduce the food effect as compared to commercial products. A method of preparation of the said composition is also disclosed. Additionally, the invention pertains to the methods of treating certain cancers in mammalian subjects using the said composition.[French]
La présente invention concerne une composition pharmaceutique stable d'abiratérone ou un sel pharmaceutiquement acceptable associé. En particulier, l'invention concerne une composition pharmaceutique stable comprenant une nanosuspension d'abiratérone ou d'un sel pharmaceutiquement acceptable associé qui réduit la dose, diminue la charge médicamenteuse, améliore la biodisponibilité de l'abiratérone dans des conditions de jeûne et réduit l'effet alimentaire par comparaison avec des produits commerciaux. Un procédé de préparation desdites compositions est également divulgué. De plus, l'invention concerne les méthodes de traitement de certains cancers chez des sujets mammifères à l'aide de ladite composition.